According to a study of FDA approval of cardiac electronic implantable devices, many of the models in current use were not required to undergo clinical testing.
The FDA designates a medical device as Class III if it “presents a potential, unreasonable risk of illness or injury.” For such devices, manufacturers are required to submit clinical data to support their claims through a premarket approval (PMA) process. However, if changes to approved Class III devices are considered incremental innovations, they can bypass the PMA requirement of clinical data via a supplement pathway.
These investigators used the FDA database to determine the frequency by which supplement pathways are used for approval of changes to cardiac implantable electronic devices (CIEDs; including implantable cardioverter-defibrillators, pacemakers, and cardiac resynchronization therapy devices) and the characteristics of the appr…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association